Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership
Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership…
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH Professional audiences…
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis Professional…
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration…
AI in Healthcare and Digital Health Video Recap—February 9, 2026
This biweekly AI in Healthcare and Digital Health video recap covers major…
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance…
AI in Healthcare and Digital Health Today—February 9, 2026
This week's AI in Healthcare and Digital Health update covers key…
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause Professional…
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D…